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“Disease is not just going to stay in prison. We are all going home. We are 
going out to our families. It affects society.”
Harold (“Buck”) Griffin 
 La Macaza Institution, Quebec1 
H
epatitis  C  virus  (HCv)  is  inCreasingly  a   
serious health issue for people living with HIV 
in the developed world, where more than 30% of 
HIV-positive individuals are also estimated to be infected 
with HCV.1 Untreated, HIV/HCV co-infection accelerates 
the progression to cirrhosis and its many complications.2 
Unfortunately, the treatment of HCV in the setting of HIV 
is also associated with lower response rates and is com-
plicated by drug interactions and toxicity.3 In this issue of 
Open Medicine, Rourke and colleagues4 present the find-
ings of their research on the social determinants of health 
associated with HIV/HCV co-infection. In this cohort 
study, co-infected individuals were more likely to report 
illicit drug use, a history of homelessness and a history of 
incarceration than those infected with HIV alone.
These may not be novel findings with respect to HCV 
and HIV demography. Previous studies have identified 
injection drug use (IDU) as the major risk factor for 
acute HCV infection and a major risk factor for HIV in-
fection.5,6 IDU, in combination with lack of access to ster-
ilized needles and rigs, previous incarceration, tattooing 
and high-risk sexual behaviours, is responsible for most 
of the new HCV infections in prisons.7   Both HIV and 
HCV flourish in prisons: we already know that the preva-
lence of HIV and HCV infection in Canadian prisons may 
be as much as 10 and 20 times higher, repectively, than 
in the general Canadian population.1 It is not surprising 
that the most marginalized among those living with HIV 
are also the most likely to be co-infected with HCV.  
The ethical dilemma arising from these findings is 
twofold. First, this study corroborates earlier findings 
that when we incarcerate individuals, whether with 
the intention of punishment, reform, or the protection 
of society, we do more than curtail their civil rights: we 
also place the incarcerated at high risk of infection and 
disease. Second, because inmates do not remain in jail 
indefinitely, we then wittingly expose the population at 
large to potential infection when prisoners are returned 
to the community. It is time to stop being polite about 
the facts: above and beyond citing IDU and history of in-
carceration as risk factors for HIV and HCV infection, 
we need to be explicit that the experience of being incar-
cerated is itself a likely mode of infection. A recent sys-
tematic review regarding tuberculosis rates in prisons 
acknowledged the  paucity of reliable data on the subject 
but estimated that 8.5% of cases of tuberculosis in the 
general population of high-income countries (mostly US 
data) is attributable to exposure to tuberculosis in pris-
ons.9 Prisons very specifically function as a focal point of 
disease transmission.
Where do we assume responsibility in this regard? In 
2008/2009, a total of 39  098 people were incarcerated 
in Canada; this represents an incarceration rate of 117 
per 100  000 population.10 Although lower than the rate 
in the United States, Canada’s incarceration rate remains 
higher than that of most Western European countries.10 
The current Canadian government has called for and 
implemented “tough on crime” laws that will lead to the 
imprisonment of more people or longer periods of time.11  
We must examine the public health impact of intensify-
ing incarceration legislation    —both within and beyond 
prison walls. We need to amplify the surveillance and 
treatment of infectious diseases in prison settings and to 
implement strategies, such as prison-based needle and 
syringe programs12 and addiction treatment13 that will 
improve and protect the health of prisoners and those 
working with them. And, although confirming associa-
tions between marginalization and disease is important, 
we equally and urgently need to improve the health and 
health care of those most at risk, with the hope of re-
ducing the burden of HIV and HCV in the community. 
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